

Supplementary Table 1. Frequency and dosage of concomitant heart failure medication in the different age groups of the LENA subjects.

	Age group 1 (n = 3)		Age group 2 (n = 12)		Age group 3 (n = 13)		Age group 4 (n = 7)	
Concomitant medication	Frequency	Dosage	Frequency	Dosage	Frequency	Dosage	Frequency	Dosage
	n (%)	Median (Range)	n (%)	Median (Range)	n (%)	Median (Range)	n (%)	Median (Range)
Furosemide (mg/kg/day)	3 (100)	2.30 (1.71-3.05)	12 (100)	1.22 (0.80-1.94)	12 (92.3)	1.40 (0.63-3.2)	6 (85.7)	1.27 (0.27-2.25)
Spirinolactone (mg/kg/day)	3 (100)	1.15 (0.86-1.83)	11 (91.7)	0.78 (0.40-1.88)	9 (69.2)	0.85 (0.39-0.98)	5 (71.4)	0.65 (0.27-0.88)
Digoxin (µg/kg/day)	0 (0)	-	1 (8.3)	14.93	0 (0)	-	2 (28.6)	10.98 (10.91-11.06)
Carvedilol (mg/kg/day)	0 (0)	-	0 (0)	-	0 (0)	-	1 (14.3)	0.55
Milrinone (µg/kg/min)	0 (0)	-	0 (0)	-	1 (7.7)	0.30-0.45 ¹	0 (0)	-
No concomitant medication	0 (0)	-	0 (0)	-	1 (7.7)	-	1 (14.3)	-

Note.

¹During the observation period, doses between 0.3 and 0.45 µg/kg/min were administered.

Supplementary Table 2. Frequency and dosage of concomitant heart failure medication in the LENA subjects with asymptomatic and symptomatic heart failure.

Concomitant medication	Predose				After 4.7 ± 1.6 days of enalapril therapy			
	Asymptomatic heart failure (n = 8)		Symptomatic heart failure (n = 27)		Asymptomatic heart failure (n = 8)		Symptomatic heart failure (n = 21)	
	Frequency n (%)	Dosage Median (Range)	Frequency n (%)	Dosage Median (Range)	Frequency n (%)	Dosage Median (Range)	Frequency n (%)	Dosage Median (Range)
Furosemide (mg/kg/day)	6 (75)	0.95 (0.63-1.39)	27 (100)	1.57 (0.27-3.20)	7 (87.5)	1.18 (0.95-1.77)	21 (100)	1.57 (0.27-3.05)
Spironolactone (mg/kg/day)	5 (62.5)	0.95 (0.57-0.98)	23 (85.2)	0.8 (0.27-1.88)	7 (87.5)	0.88 (0.57-0.98)	19 (90.5)	0.85 (0.27-1.88)
Digoxin (µg/kg/day)	0 (0)	-	3 (11.1)	11.06 (10.91-14.93)	1 (12.5)	11.06	1 (4.8)	14.93
Carvedilol (mg/kg/day)	0 (0)	-	1 (3.7)	0.55	1 (12.5)	0.55	0 (0)	-
Milrinone (µg/kg/min)	0 (0)	-	1 (3.7)	0.30-0.45 ¹	0 (0)	-	0 (0)	-
No concomitant medication	2 (25)	-	0 (0)	-	1 (12.5)	-	0 (0)	-

Note.

¹During the observation period, doses between 0.3 and 0.45 µg/kg/min were administered.